Ilaris 150mg Injection (Canakinumab)
Prescription RequiredManufactured By
Novartis
Pack Of
1
Salt Composition
Canakinumab
Storage
Refrigerate; do not freeze
- Quality-Assured Medicines
- Verified Suppliers
- Secure & Protective Packaging
- Worldwide Delivery
Safe and Secure
Your health and safety are our top priority. All our medicines are sourced from trusted suppliers, thoroughly tested, and approved for use. We follow strict quality control standards to ensure every product is safe, effective, and reliable. You can enquire knowing your wellness is in good hands.
Overview
Ilaris 150mg/mL Injection (Canakinumab) contains Canakinumab 150mg in 1mL (150mg/mL solution; presentation-specific). It is a interleukin-1 beta (il-1β) inhibitor; human monoclonal antibody. Used for specified periodic fever syndromes including CAPS, TRAPS, HIDS/MKD and FMF; Still’s disease including systemic juvenile idiopathic arthritis and adult-onset Still’s disease; and certain gout flares where relevant. Regimens are indication- and weight-specific.
Its mechanism is: Selectively binds IL-1β and blocks interaction with its receptor, reducing inflammatory signalling. Treatment with Ilaris 150mg/mL Injection requires a clinician to match the indication, dose, comorbidities, previous therapies and concurrent medicines. Clinical benefits and adverse effects of Ilaris 150mg/mL Injection are specific to the underlying disease and patient population.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Full medicine name | Ilaris 150mg/mL Injection (Canakinumab) |
| Composition | Canakinumab 150mg in 1mL (150mg/mL solution; presentation-specific) |
| Form | Solution for subcutaneous injection; single-dose vial; prefilled pen presentation exists in some markets |
| Class | Interleukin-1 beta (IL-1β) inhibitor; human monoclonal antibody |
| Route | Subcutaneous |
| Typical administration context | For Still’s disease, a reference regimen is 4mg/kg (maximum 300mg) subcutaneously every 4 weeks for patients at least 7.5kg. Certain adult gout-flare regimens use 150mg once, with at least 12 weeks before retreatment. Periodic fever schedules vary by syndrome, age, weight and response. |
| Exact pack size | 1 single-use vial per carton |
Uses and Indications
Ilaris 150 mg/mL Injection contains canakinumab, a biologic medicine that belongs to the interleukin-1 beta (IL-1β) inhibitor class. It works by blocking IL-1β, a protein involved in inflammation, helping control certain autoinflammatory diseases.
How Ilaris 150mg Injection Works
Ilaris 150mg/mL Injection contains Canakinumab which selectively binds IL-1β and blocks interaction with its receptor, reducing inflammatory signalling. By altering the relevant inflammatory or infectious pathway, Canakinumab injection can improve disease-related outcomes when appropriately selected and monitored; it does not eliminate the need for ongoing disease assessment.
Clinical Evidence for Ilaris 150mg Injection
Randomized studies in CAPS and other autoinflammatory syndromes, Still’s disease and gout flares establish condition-specific effects; results must be attributed to the studied population. Study endpoints and effect sizes must be quoted only with the relevant trial, comparator, dose, time point and patient population; these should not be generalized across indications or attributed to a different commercial brand.
Side Effects of Ilaris 150mg Injection
Many side effects require no attention and go away when your body gets used to Ilaris 150mg/mL Injection. See your doctor if your side effects do not go away or if you are concerned about them.
Common side effects of Ilaris 150mg/mL injection (Canakinumab) are:
- cold symptoms
- pneumonia
- runny nose
- sore throat
- urinary tract infection
- nausea, vomiting, and diarrhea (gastroenteritis)
- stomach pain
- upper respiratory tract infection
- urinary tract infection
- headache,
- abdominal discomfort,
- injection-site reactions
- infections.
- injection site reactions (such as redness, swelling, warmth, or itching)
The likelihood of a particular event depends on indication, dose, treatment duration and other medicines. New, persistent or severe symptoms require medical review.
Critical Safety Warning
Serious infections; hypersensitivity including DRESS; neutropenia; potential macrophage activation syndrome in Still’s disease; live-vaccine precautions. Seek prompt assessment for severe infection, breathing difficulty, widespread rash, chest pain, new neurological symptoms or other serious symptoms as relevant to the Canakinumab 150mg/mL Injection (Ilaris).
Ilaris 150mg Injection Dosage and How To Take It
| Clinical situation | Dose |
|---|---|
| Exact product | Ilaris 150mg/mL Injection (Canakinumab) |
| Strength / concentration | Canakinumab 150mg in 1mL (150mg/mL solution; presentation-specific) |
| Administration | For Still’s disease, a reference regimen is 4mg/kg (maximum 300mg) subcutaneously every 4 weeks for patients at least 7.5kg. Certain adult gout-flare regimens use 150mg once, with at least 12 weeks before retreatment. Periodic fever schedules vary by syndrome, age, weight and response. |
| Dose adjustment | Clinician-directed; review renal/hepatic function, indication, weight and interactions as applicable. |
| Do not change independently | Do not double doses or change injection interval without prescriber guidance. |
Ilaris 150mg Injection Missed Dose
For Ilaris 150mg/mL Injection, take a missed dose when remembered unless it is close to the next scheduled dose; do not double. For scheduled biologic injections, contact the treatment team to agree on the next administration date. Follow the exact Canakinumab 150mg/mL Injection (Ilaris) leaflet for the prescribed indication.
Safety Advice for Ilaris 150mg Injection
| Category | Status | Guidance |
|---|---|---|
| Pregnancy / breastfeeding | Specialist consultation | Individual specialist risk–benefit assessment. |
| Infection / vaccination | Infection risk assessment | Review active infection and vaccination status before immunomodulatory treatment. |
| Kidney / liver disease | Medical supervision | Assess organ function and dosing suitability. |
| Other medicines | Interaction screening | Check prescription, OTC and herbal products for interactions. |
| Storage / handling | Refrigerate; do not freeze. | Follow the actual manufacturer label; injection presentations may require refrigeration and protection from freezing. |
Monitoring During Ilaris 150mg Injection Treatment
Screen for TB and active infection; CBC/differential; infection surveillance; disease activity and inflammatory markers; vaccination review. Follow-up frequency is individualized to the disease, dose, treatment duration and baseline risk.
Ilaris 150mg Injection Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Product identity | Ilaris 150mg/mL Injection (Canakinumab) |
| Strength / concentration | Canakinumab 150mg in 1mL (150mg/mL solution; presentation-specific) |
| Dosage form | Solution for subcutaneous injection; single-dose vial; prefilled pen presentation exists in some markets |
| Mechanism | Selectively binds IL-1β and blocks interaction with its receptor, reducing inflammatory signalling. |
| Dosing context | For Still’s disease, a reference regimen is 4mg/kg (maximum 300mg) subcutaneously every 4 weeks for patients at least 7.5kg. Certain adult gout-flare regimens use 150mg once, with at least 12 weeks before retreatment. Periodic fever schedules vary by syndrome, age, weight and response. |
| Principal warning | Serious infections |
| Pack details | 1 single-use vial per carton |
Ilaris 150mg Injection Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Other IL-1 inhibitors (biologic medicines) | May increase the risk of serious infections. | Avoid concurrent use unless specifically directed by a specialist. |
| TNF inhibitors | May increase the risk of serious infections when combined with canakinumab. | Consult your specialist before combining treatments. |
| Live vaccines | May increase the risk of infection or reduce vaccine safety during treatment. | Avoid live vaccines during treatment unless your specialist advises otherwise. |
| Other immunosuppressants | May increase the risk of infections. | Inform your doctor about all medicines you take. |
FAQs About Ilaris 150mg Injection
What is the exact medicine name?
Ilaris 150mg/mL Injection (Canakinumab)
What is its active ingredient and strength?
Canakinumab 150mg in 1mL (150mg/mL solution; presentation-specific)
What is the dosage form of Canakinumab 150mg/mL Injection (Ilaris)?
Canakinumab 150mg/mL Injection (Ilaris) subcutaneous injection; single-dose vial; prefilled pen presentation exists in some markets.
What is ilaris 150mg/ml injection used for?
Used for specified periodic fever syndromes including CAPS, TRAPS, HIDS/MKD and FMF; Still’s disease including systemic juvenile idiopathic arthritis and adult-onset Still’s disease; and certain gout flares where relevant. Regimens of Ilaris 150mg/mL Injection are indication- and weight-specific.
How does ilaris 150mg/ml injection work?
Ilaris 150mg/mL Injection contain Canakinumab, which selectively binds to IL-1β and blocks interaction with its receptor, reducing inflammatory signalling.
How is ilaris 150mg/ml injection administered?
For Still’s disease, a reference regimen is 4mg/kg (maximum 300mg) subcutaneously every 4 weeks for patients at least 7.5kg. Certain adult gout-flare regimens use 150mg once, with at least 12 weeks before retreatment. Periodic fever schedules vary by syndrome, age, weight and response.
What are the main risks associated with ilaris 150mg/ml injection?
Serious infections; hypersensitivity including DRESS; neutropenia; potential macrophage activation syndrome in Still’s disease; live-vaccine precautions.
What monitoring is needed with ilaris 150mg/ml injection?
Screen for TB and active infection; CBC/differential; infection surveillance; disease activity and inflammatory markers; vaccination review.
Can I use Canakinumab 150mg/mL Injection (Ilaris) with other immunosuppressants?
Avoid other biologic IL-1 blockers and TNF inhibitors unless specialist-directed; avoid live vaccines during treatment with Canakinumab 150mg/mL Injection (Ilaris)
What if I miss a dose of ilaris 150mg/ml injection?
Do not double; consult the Ilaris 150mg/mL Injection leaflet or treating clinician, particularly for injections.
Does the strength indicate the total treatment course?
No. The strength identifies Ilaris 150mg/mL injection presentation; dose and duration depend on indication of injection.
Can the concentration of ilaris 150mg/ml injection be assumed from the brand name?
No. Check the Ilaris 150mg/mL Injection (Canakinumab) pack and device before publishing concentration and volume.
References
- Primary molecule/product prescribing information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e
- National library of medicine. The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells. https://pmc.ncbi.nlm.nih.gov/articles/PMC11884680
- hres ca. PRODUCT MONOGRAPH. ILARIS (canakinumab). Https://pdf.hres.ca/dpd_pm/00044414.PDF
- Drug and Health Product Portal. Summary Safety Review - Ilaris (canakinumab) – Assessing the Potential Risk of Drug Reaction with
- Eosinophilia and Systemic Symptoms https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1732291653402
- Science Direct. Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases. https://www.sciencedirect.com/science/article/pii/S1367593115001507
Marketer Details
Novartis
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
